title: Influenza vaccination in asthma: a primary care experience.
abstract: BACKGROUND
  Despite the recommendation of the Department of Health that patients with asthma receive annual vaccination against influenza, uptake remains unsatisfactory with many patients suspicious that vaccination is harmful.
  
  
  OBJECTIVE
  To examine the effect of influenza vaccination on asthmatic patients typical of a general practice setting.
  
  
  METHODS
  A multicentre study with 56 patients participating from 14 practices in England and Scotland. Patients completed peak expiratory flow rate (PEFR) and symptom diaries for two weeks before and two weeks after influenza vaccination.
  
  
  RESULTS
  A non-significant fall in baseline PEFR of 10.5 l/min, from an average of 431.5 l/min, was observed after influenza vaccination, representing a 2% change from baseline. A significant increase in night time reliever use of 0.17 puffs per night (P < 0.01) was found. Non-significant increases in number of nights per week with sleep disturbed due to asthma, severity of night-time and day-time symptoms, and day-time reliever use were also noted.
  
  
  CONCLUSIONS
  Influenza is an important cause of morbidity and mortality in asthmatics. This study confirms the safety of influenza vaccination in patients with asthma typical of those seen in primary care. General practitioners need not hesitate in recommending this valuable intervention to their asthmatic patients and should consider ways in which uptake can be improved.
authors.affiliation: Astra Pharmaceuticals Ltd, King's Langley, Hertfordshire.
authors.forename: A
authors.initials: A
authors.lastname: Innes
authors.forename: E
authors.initials: E
authors.lastname: Beresford
authors.forename: J
authors.initials: J
authors.lastname: Bedford
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage; D001249:Asthma / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000150:complications / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000502:physiology
chemical_list: D018927:Anti-Asthmatic Agents; D007252:Influenza Vaccines